- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Why a Patient With Multiple Myeloma Might Decline Stem Cell Transplant: Mansi Shah, MD
Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, says Mansi Shah, MD.
Autologous stem cell transplant remains a key first-line option in multiple myeloma. However, real-world barriers from extended downtime to increased caregiver dependency can still lead patients to decline the procedure, according to Mansi Shah, MD, clinical director of multiple myeloma at Rutgers Cancer Institute.
Shah previously outlined how stem cell transplant, chimeric antigen receptor (CAR) T-cell therapy, and bispecifics are sequenced in practice. In this interview, she explains the practical realities that influence patient choice.
This transcript has been lightly edited; captions were auto-generated.
Transcript
Why might a patient with multiple myeloma choose not to undergo stem cell transplantation?
It's the downtime; it's the potential toxicity. Not every institution is able to do a stem cell transplant outpatient. On average, at our institution, I counsel patients that they will be admitted for about 2 [to] 2-and-a-half weeks, and then they’re still immunocompromised after the fact. Typically, that immune reconstitution can take anywhere from 2 to 3 months after a stem cell transplant.
If they're the primary financial breadwinner of their family, that's tough. They might need someone to be their caregiver in that time period. Especially for young patients who are just starting families and/or have young families, this is a very difficult thing for them to get through. Sometimes patients prefer a longer therapy that might be ongoing just so they don't have this little downtime, and then they can't deal with the time off from work or afford it financially or have the caregivers.
It's a similar kind of restraint with CAR T where at least for the first 30 to 60 days, patients are limited—they're not able to drive because of the potential neurotoxicities. But I do think in terms of the myelosuppression, or effect on the blood counts and on organs, CAR T is a little bit better tolerated than a stem cell transplant.
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
